Last updated: September 9, 2026
Fostamatinib disodium, marketed as Tavalisse in the United States, is a spleen tyrosine kinase inhibitor approved for adults with chronic immune thrombocytopenia who have had an insufficient response to prior treatment. Rigel Pharmaceuticals owns and commercializes Tavalisse in the U.S.; Grifols has commercial rights in Europe and selected territories. The drug has developed into a durable specialty-pharmaceutical franchise, with U.S. revenue growth driven by increased prescribing, broader hematology adoption, and demand for an oral treatment after failure of thrombopoietin-receptor agonists.
The commercial risks are concentrated in a narrow market, reimbursement access, competition from established platelet-raising therapies, and eventual generic entry after regulatory and patent protection declines.
What is fostamatinib disodium and how does Tavalisse work?
Fostamatinib disodium is the disodium salt prodrug of R406, an active spleen tyrosine kinase inhibitor. Tavalisse inhibits Fc-receptor signaling in macrophages, reducing antibody-mediated platelet destruction. It differs mechanistically from thrombopoietin-receptor agonists such as eltrombopag, avatrombopag, and romiplostim, which stimulate platelet production.
The U.S. Food and Drug Administration approved Tavalisse on May 17, 2018, for adults with chronic immune thrombocytopenia who had an insufficient response to a previous treatment. The approved regimen begins at 100 mg twice daily and may increase to 150 mg twice daily based on platelet response and tolerability [1].
What clinical and commercial attributes support Tavalisse demand?
Tavalisse has several commercially relevant characteristics:
- Oral twice-daily administration.
- A mechanism distinct from thrombopoietin-receptor agonists.
- Use after failure of corticosteroids, immunoglobulins, rituximab, splenectomy, or other therapies.
- No requirement for platelet transfusion or infusion-center administration.
- Potential use in patients who do not respond adequately to TPO-receptor agonists.
The pivotal Phase 3 FIT studies produced a stable platelet response in a minority of heavily pretreated patients. In FIT-1 and FIT-2, the durable response rate was approximately 18%, compared with 2% for placebo. Diarrhea, hypertension, nausea, elevated liver enzymes, and neutropenia are the principal safety and monitoring considerations [2].
How large is the market for fostamatinib disodium?
The addressable market is the chronic immune thrombocytopenia segment rather than the entire hematology market. ITP affects an estimated 3.3 adults per 100,000 annually, with a smaller chronic population requiring repeated treatment. Commercial value is concentrated among patients with persistent disease, bleeding risk, and failure of multiple therapies.
Tavalisse competes in a treatment sequence that includes:
| Therapy |
Active ingredient |
Route |
Principal market position |
| Tavalisse |
Fostamatinib |
Oral |
Later-line chronic ITP |
| Promacta/Revolade |
Eltrombopag |
Oral |
Broad TPO-RA use |
| Doptelet |
Avatrombopag |
Oral |
Chronic ITP and other platelet indications |
| Nplate |
Romiplostim |
Injection |
Chronic ITP |
| Rituxan |
Rituximab |
Infusion |
Immune-directed treatment |
| WinRho and IVIG |
Various |
Infusion/injection |
Acute platelet elevation and rescue treatment |
The main commercial distinction is that Tavalisse is not primarily dependent on stimulating platelet production. That gives physicians an alternative after TPO-receptor agonist failure, but its later-line positioning limits total patient volume.
What are Rigel Pharmaceuticals’ Tavalisse revenues?
Tavalisse has been Rigel’s principal commercial growth asset. Public company filings show a multiyear increase in net product sales as the company expanded its hematology field force and improved physician awareness.
| Fiscal year |
Approximate Tavalisse net product sales |
Commercial interpretation |
| 2020 |
$46 million |
Early commercial ramp |
| 2021 |
$78 million |
Wider U.S. adoption |
| 2022 |
$106 million |
Increased later-line use |
| 2023 |
$136 million |
Continued prescription growth |
| 2024 |
Approximately $150 million |
Mature growth trajectory |
The figures are based on Rigel annual reports and company disclosures; reported totals can differ depending on whether the company presents product sales separately from royalties, collaboration revenue, and other product revenue [3, 4].
Tavalisse revenue growth has been important because Rigel historically operated with substantial research, development, selling, and administrative expenses. A larger recurring product-sales base improves operating leverage, but profitability remains sensitive to commercial spending, milestone obligations, manufacturing costs, and revenue from other products.
What is the financial trajectory for Rigel Pharmaceuticals?
Rigel’s financial trajectory has shifted from a development-stage biotechnology model toward a commercial specialty-pharmaceutical model. The company’s revenue base expanded after Tavalisse commercialization and later benefited from additional products and licensing arrangements.
The principal financial drivers are:
- Tavalisse prescription growth in the U.S.
- Net pricing after rebates and commercial discounts.
- European and international royalty income.
- Sales force productivity in hematology.
- Development and commercialization costs for additional products.
- The timing of generic or competing-product entry.
Tavalisse is strategically important because it is a branded, orally administered therapy with repeat-use potential. Its revenue is less dependent on a single acute treatment event than products used only for rescue care.
What patents protect Tavalisse and fostamatinib disodium?
Tavalisse protection is based on a combination of compound, formulation, and method-of-use intellectual property. Key U.S. patent families associated with fostamatinib include patents issued from applications covering substituted thiazole compounds and pharmaceutical uses.
Publicly identified U.S. patents associated with the fostamatinib estate include:
| Patent |
General subject matter |
Relevance |
| U.S. Patent No. 8,461,189 |
Fostamatinib-related substituted thiazole compounds |
Core compound protection |
| U.S. Patent No. 9,018,311 |
Fostamatinib and related therapeutic applications |
Later patent protection |
| U.S. Patent No. 10,583,110 |
Later-issued pharmaceutical or use claims |
Potentially relevant to later entry analysis |
The controlling scope depends on the claims, terminal disclaimers, patent-term adjustment, pediatric extensions, and current FDA Orange Book listings. A patent number alone does not establish the date on which a generic can lawfully launch.
What is the Orange Book status of Tavalisse?
Tavalisse is listed in the FDA Orange Book under NDA 209299. The Orange Book is the primary U.S. regulatory source for determining whether FDA-listed patents and associated use codes must be addressed by an abbreviated new drug application applicant [5].
The principal regulatory-exclusivity milestone was the drug’s seven-year orphan-drug exclusivity period, which began with the May 17, 2018 approval. Absent an applicable extension, that period ended in May 2025. Orphan exclusivity prevents FDA approval of the same drug for the same indication, but it does not prevent all competing products or all uses outside the protected indication.
Generic entry also depends on:
- The status of FDA-listed patents.
- Paragraph IV certifications.
- Any patent litigation filed within 45 days.
- Court-ordered stays.
- Non-infringement or invalidity outcomes.
- The generic applicant’s ability to satisfy formulation and bioequivalence requirements.
When does fostamatinib lose exclusivity?
Fostamatinib’s orphan-drug exclusivity ended in 2025, while patent protection may extend beyond that date depending on the applicable Orange Book patents and their adjusted expiration dates. Loss of orphan exclusivity does not automatically create immediate generic competition.
A generic applicant can seek approval before patent expiration by filing a Paragraph IV certification. If the patent holder sues within the statutory period, FDA approval may be stayed for up to 30 months, subject to court decisions and later regulatory developments [6].
The practical entry timeline therefore has several possible outcomes:
| Scenario |
Likely commercial effect |
| No ANDA filing |
Continued branded sales after orphan exclusivity |
| Paragraph III filing |
Launch delayed until relevant patent expiry |
| Paragraph IV filing without litigation |
Potential early approval and launch |
| Paragraph IV filing followed by litigation |
Possible 30-month regulatory stay |
| Successful patent challenge |
Earlier generic competition |
| Settlement with delayed entry |
Entry date controlled by agreement terms |
No broadly publicized, market-disrupting Paragraph IV challenge had materially altered Tavalisse sales through the latest company reporting period. The absence of a disclosed challenge does not eliminate future generic risk.
What formulation and manufacturing barriers protect Tavalisse?
Tavalisse is an oral tablet. The formulation is less technically complex than an injectable biologic or long-acting delivery system, which generally lowers the manufacturing barrier for an approved generic.
The principal barriers are regulatory and commercial rather than manufacturing-related:
- Demonstrating bioequivalence for the active moiety.
- Matching dissolution and exposure characteristics.
- Establishing a compliant supply chain for fostamatinib.
- Addressing Orange Book patents and method-of-use claims.
- Building a commercial channel in a relatively small specialty market.
Fostamatinib manufacturing does not create the same level of entry barrier as monoclonal-antibody production. A capable generic manufacturer with adequate regulatory resources could reproduce the oral dosage form more readily than a complex biologic.
Which companies challenge Tavalisse in the ITP market?
The strongest competitive threats come from marketed platelet-raising therapies rather than direct fostamatinib copies.
Promacta and Revolade
Eltrombopag is an established oral TPO-receptor agonist with broad physician familiarity. Its advantages include a large clinical history and use across several indications. Liver monitoring, dietary restrictions, and drug-interaction considerations can limit convenience.
Doptelet
Avatrombopag is an oral TPO-receptor agonist marketed by Dova Pharmaceuticals, now part of Swedish Orphan Biovitrum. It competes directly for oral chronic ITP use and has a differentiated dosing and food profile.
Nplate
Romiplostim is an injectable TPO-receptor agonist marketed by Amgen. Its injection requirement can be a disadvantage, but physician familiarity and established efficacy support continued use.
Rituximab, splenectomy, and immunosuppressive therapies
These treatments remain alternatives for selected patients, especially where physicians seek immune modulation or a longer treatment-free interval. Their efficacy, safety, and durability profiles differ substantially from Tavalisse.
What licensing deals affect fostamatinib disodium?
Rigel has used regional licensing to extend Tavalisse commercialization beyond the U.S. Grifols obtained rights to commercialize fostamatinib in Europe and other territories under an agreement covering the product marketed as Tavlesse. Regional licensing reduces Rigel’s direct commercial investment but transfers part of the product economics to royalties, milestones, or profit-sharing arrangements [7].
International commercialization is important because ITP treatment patterns and reimbursement rules vary substantially across markets. European uptake has been slower than U.S. revenue growth, reflecting country-by-country reimbursement, hospital prescribing practices, and later market access.
What is the litigation and settlement status for Tavalisse?
The relevant legal risks are expected to center on Orange Book patent challenges, generic approval timing, and licensing terms rather than broad product-liability litigation. A Paragraph IV case would determine whether a challenger can launch before the relevant patent expiration dates.
No major publicly disclosed settlement agreement had established an industry-wide early generic launch date for Tavalisse through the latest available company disclosures. The absence of a settlement leaves the market exposed to future litigation-driven entry risk.
How strong is the fostamatinib patent estate?
The estate is commercially useful but not comparable to the protection around a newly launched biologic with long remaining exclusivity. Its strength has three dimensions:
- Orphan-drug exclusivity provided a seven-year regulatory barrier.
- Core and follow-on patents may extend protection beyond orphan exclusivity.
- The oral formulation is comparatively easier to reproduce than a complex biologic.
The primary weakness is that a later-line oral small molecule can become vulnerable to generic substitution once enforceable patents expire. The size of the ITP market may also limit the incentive for multiple generic companies to invest in litigation, which can delay competition even after some legal protections lapse.
What generic launch risks exist for fostamatinib?
The most likely commercial sequence is gradual erosion rather than an immediate collapse in sales. Tavalisse has a specialist prescriber base, and payers may initially maintain branded coverage where physicians value clinical experience or where generic supply is limited.
Potential launch effects include:
- Price discounts from the first generic entrant.
- Greater payer pressure on branded net pricing.
- Reduced new-patient starts.
- Substitution in stable patients.
- Lower royalty value in territories with generic competition.
- Increased demand for patient-support and adherence programs.
A single generic entrant could pressure price materially, while multiple entrants would create sharper erosion. The relatively small ITP population may reduce the speed of multi-generic commoditization.
How does Tavalisse compare with eltrombopag and avatrombopag?
| Factor |
Fostamatinib |
Eltrombopag |
Avatrombopag |
| Mechanism |
SYK inhibition |
TPO-receptor agonism |
TPO-receptor agonism |
| Administration |
Oral |
Oral |
Oral |
| Typical position |
Later-line ITP |
Broad chronic use |
Chronic ITP and other uses |
| Key safety monitoring |
Blood pressure, liver enzymes, neutropenia |
Liver tests, thrombosis, dietary interactions |
Thrombosis and platelet monitoring |
| Main commercial strength |
Different mechanism after prior failure |
Established clinical adoption |
Oral alternative with differentiated use |
| Principal limitation |
Modest durable-response rate |
Monitoring and interaction burden |
Smaller commercial footprint |
Tavalisse’s value proposition is strongest when a patient has failed or inadequately responded to a TPO-receptor agonist. It is less likely to displace first-line or early-line treatment across the full ITP population.
What is the revenue outlook for fostamatinib?
Near-term revenue growth depends on continued U.S. penetration rather than major expansion of the treated population. The product can maintain growth through:
- Earlier use within later-line treatment.
- Greater use after TPO-receptor agonist failure.
- Improved payer access.
- International reimbursement gains.
- Additional indications, if supported by clinical data and approved by regulators.
The principal downside risks are limited market size, treatment discontinuation from adverse events, competing oral therapies, and generic entry. Tavalisse remains a valuable commercial asset for Rigel, but its long-term revenue profile will depend more on lifecycle management and geographic expansion than on broad population growth.
Key Takeaways
- Fostamatinib disodium is marketed in the U.S. as Tavalisse for adults with chronic ITP after inadequate response to prior treatment.
- The drug’s mechanism is differentiated from TPO-receptor agonists, supporting use after eltrombopag, avatrombopag, or romiplostim failure.
- U.S. Tavalisse revenue increased from roughly $46 million in 2020 to approximately $150 million in 2024.
- FDA orphan-drug exclusivity began in May 2018 and ended in May 2025, subject to the statutory scope of the designation.
- Patent and Paragraph IV developments, rather than orphan exclusivity alone, will determine generic launch timing.
- Tavalisse has a commercially useful but finite small-molecule patent estate.
- Rigel’s principal financial exposure is continued U.S. prescription growth and the timing of generic price erosion.
- Grifols’ European commercialization provides geographic reach but reduces Rigel’s direct economics in those territories.
FAQs
Is fostamatinib disodium the same as Tavalisse?
Yes. Tavalisse is the U.S. brand name for fostamatinib disodium tablets. Fostamatinib is converted in the body to R406, the active SYK inhibitor.
Is fostamatinib a biologic or a generic drug?
Fostamatinib is a small-molecule pharmaceutical, not a biologic. Tavalisse is the branded reference product, and future competitors would generally seek approval through the ANDA generic-drug pathway.
Does fostamatinib compete with Promacta?
Yes. Fostamatinib competes with Promacta, whose active ingredient is eltrombopag. The drugs have different mechanisms and are often positioned at different points in the chronic ITP treatment sequence.
What is the main commercial weakness of Tavalisse?
Its main weakness is later-line positioning in a relatively small patient population. The modest durable-response rate and adverse-event monitoring requirements also limit broad use.
Could Tavalisse sales continue growing after orphan exclusivity ends?
Yes. Orphan exclusivity expiration does not automatically result in generic approval. Sales can continue growing if no generic launches, if patent protection remains enforceable, or if physician adoption and international commercialization offset competitive pressure.
References
- U.S. Food and Drug Administration. (2018). FDA approves new treatment for adults with chronic immune thrombocytopenia. https://www.fda.gov
- Bussel, J., Arnold, D. M., Grossbard, E., Mayer, J., Trelinski, J., Genest, J., ... Tarantino, M. D. (2018). Fostamatinib for the treatment of chronic immune thrombocytopenia. New England Journal of Medicine, 378(14), 1335-1346.
- Rigel Pharmaceuticals, Inc. (2024). Annual report on Form 10-K for the fiscal year ended December 31, 2023. U.S. Securities and Exchange Commission. https://www.sec.gov
- Rigel Pharmaceuticals, Inc. (2025). Annual report on Form 10-K for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission. https://www.sec.gov
- U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book, NDA 209299. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov
- Grifols, S.A. (2018). Grifols and Rigel enter agreement for European commercialization of fostamatinib. https://www.grifols.com
